Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of Antiplatelet Therapy.

Annual review of pharmacology and toxicology - 20 Jan 2023

Castrichini Matteo, Luzum Jasmine A, Pereira Naveen

Abstract excerpt

Antiplatelet therapy is used in the treatment of patients with acute coronary syndromes, stroke, and those undergoing percutaneous coronary intervention. Clopidogrel is the most widely used antiplatelet P2Y12 inhibitor in clinical practice. Genetic variation in CYP2C19 may influence its enzymatic activity, resulting in individuals who are carriers of loss-of-function CYP2C19 alleles and thus have reduced active...

Topics

Join the communities discussing this publication.

Pharmacogenetics
Clopidogrel
Cytochrome P-450 CYP2C19
Genotype
Platelet Aggregation Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Reproducibility of Results

Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 35914768
DOI: 10.1146/annurev-pharmtox-051921-092701
PMCID: PMC9868113

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of Antiplatelet Therapy.PMID 35914768Read ↗

Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives.Semantic proximity Read ↗

CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Semantic proximity Read ↗

The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack.Semantic proximity Read ↗

Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.Semantic proximity Read ↗

The pharmacogenetics of antiplatelet agents: towards personalized therapy?Semantic proximity Read ↗

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

Pharmacogenetics of P2Y 12 receptor inhibitorsSemantic proximity Read ↗

Can CYP2C19 genotyping improve antiplatelet therapy efficacy in real-life practice? Recent advances.Semantic proximity Read ↗

Clopidogrel PharmacogeneticsSemantic proximity Read ↗

Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped?Semantic proximity Read ↗

Pharmacogenetics of antiplatelet therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.